Document is current
Any future updates will be listed below
-
Authors
Motomura, Yuma
Urai, Shin
Hirota, Yushi https://orcid.org/0000-0002-3035-4155
Takegawa, Naoki
Bando, Hironori
Yamamoto, Masaaki
Fukuoka, Hidenori
Tsuda, Masahiro
Ogawa, Wataru
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 9 August 2023
First Online: 28 August 2023
Declarations
:
: All the affiliations or financial involvement with any organization or financial conflict with the subject matter discussed in the manuscript are completely disclosed in this section. Yushi Hirota received lecture fees from Eli Lilly Japan K.K., Sanofi Aventis, Abbott Japan, Terumo Co., and Sumitomo Pharma Co. Ltd. Yushi Hirota received a research funding from Sumitomo Pharma Co., Ltd., Medtronic Japan Co., Ltd., and Kyowa Kirin Co., Ltd. Yushi Hirota received a donation from Abbott Japan. Wataru Ogawa received lecture fees from Sumitomo Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Abbott Japan, and Novo Nordisk Pharma Ltd. Wataru Ogawa received a research grant from Noster, Nippon Boehringer Ingelheim Co., Ltd., Boehringer Ingelheim Pharma GmbH&Co. KG, Co., Ltd., Eli Lilly Japan K.K., Abbott Diabetes Care UK Ltd., Sumitomo Pharma Co., Ltd., and Teijin Pharma Ltd. Wataru Ogawa received a donation from Kowa Co., Ltd., Novo Nordisk Pharma Ltd. Astellas Pharma Inc., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Yuma Motomura, Shin Urai, Naoki Takegawa, Hironori Bando, Masaaki Yamamoto, Hidenori Fukuoka, and Masahiro Tsuda declare that they have no conflict of interest.
: Yes.
: Not applicable.
: Not applicable.
